Co-Chairs & Presenters, Elizabeth A. Raetz, MD and Rachel Rau, MD prepared useful Practice Aids pertaining to acute lymphoblastic leukemia for this CME activity titled “Meeting Therapeutic Challenges in Pediatric ALL: Expert Perspectives on the Use of Asparaginase Compounds.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at http://bit.ly/38LiheG. CME credit will be available until May 18, 2022.

1. PegASNase IV
Neutralizing
Antibody
Assessment
Accelerated
Clearance
Assessment
<10% of dose
administered
10%-50% of dose
administered
>50% of dose
administered
Monitor next
dose if ASNase
continued
Continue scheduled
pegASNase
Monitor next dose; consider
increasing pegASNase or
switching to Erwinia ASNase
Switch to Erwinia
ASNase
First ASNase level
was 1.0 units/mL
Day 14 ASNase:
0.025 to <0.1 units/mL
(accelerated clearance)
Switch to Erwinia
ASNase
Draw level 1 week
after first level
ASNase result:
0.05 units/mL
Day 14 ASNase:
<0.025 units/mL
(accelerated clearance)
Day 14 ASNase:
0.1 units mL
Draw level
3-5 days after dose
ASNase result:
<0.05 units/mL
(inactivation)
Draw level
4-7 days after dose
First ASNase level
was 0.05 to
<1.0 units/mL
Utilizing Serum Amyloid A to Distinguish
Antibody-Mediated Hypersensitivity vs Infusion Reaction1
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/ZBG40
1. Bleyer A et al. Pediatr Blood Cancer. 2015;62:1102-1105.